Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-12-27 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于首发前限售股份上市流通及控股股东追加股份锁定期公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of trading restrictions on pre-IPO restricted shares and the additional lock-up period commitment by the controlling shareholder. It includes specifics about share quantities, shareholder commitments, lock-up periods, and compliance with regulatory requirements. The document references shareholder lock-up, share release dates, and shareholder commitments rather than financial results or management discussions. It is not a financial report, earnings release, or management report. It is also not a proxy statement, AGM material, or a regulatory certification. The content fits the category of announcements related to share capital changes and shareholder lock-up arrangements. Therefore, the document is best classified as a Share Issue/Capital Change (SHA) filing, as it deals with the release and lock-up of shares affecting the company's capital structure.
2017-12-27 Chinese
第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the third meeting of the third board of directors of the company 葵花药业集团股份有限公司. It details the approval of a share acquisition transaction and includes voting results and independent directors' opinions. There is no financial data, earnings information, or report publication mentioned. The content focuses on board decisions and changes related to company ownership structure. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2017-12-07 Chinese
关于收购葵花药业集团（衡水）得菲尔有限公司1,040万元股权公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of equity in a subsidiary company by the parent company. It details the transaction terms, shareholding changes, financial data of the subsidiary, and includes board meeting resolutions and independent director opinions. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or certification. The content focuses on a capital transaction involving share acquisition and changes in ownership structure. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive transaction details, not just a report publication announcement. Hence, the classification is CAP with high confidence.
2017-12-07 Chinese
独立董事关于公司第三届董事会第三次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting agenda item regarding the company's acquisition of shares in a subsidiary. It references compliance with company law, securities law, and stock exchange listing rules, and discusses the fairness and legality of the transaction. The content focuses on board-level decision-making and approval of a capital transaction rather than financial results, audit, or general regulatory announcements. It is not a full report, earnings release, or presentation. The document is a formal board/management information disclosure about a specific transaction and board approval.
2017-12-07 Chinese
关于建立中国工程院药学院士工作站的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the establishment of a new academician workstation in collaboration with a national academy. It includes details about the approval from a provincial science and technology department and the purpose of the workstation. There is no financial data, no mention of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no report publication. The document is a regulatory announcement about a corporate development related to research collaboration. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2017-11-02 Chinese
2017年第三季度报告全文
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2017 Third Quarter Report" of 葵花药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow statements, and explanations of financial changes during the period. The length is substantial (15,000 characters), and it includes comprehensive financial statements and management discussion of financial performance for the quarter. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and it is not an annual report or earnings release. Therefore, the document is best classified as an Interim / Quarterly Report (IR). 9M 2017
2017-10-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.